- Report
- November 2023
- 353 Pages
Global
From €9128EUR$9,500USD£7,849GBP
- Report
- March 2021
- 207 Pages
Global
From €2402EUR$2,500USD£2,066GBP
- Report
- January 2021
- 900 Pages
United States
From €3171EUR$3,300USD£2,726GBP
- Report
- April 2023
- 180 Pages
Global
From €7206EUR$7,500USD£6,197GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2642EUR$2,750USD£2,272GBP
Faslodex is a prescription drug used to treat hormone receptor-positive metastatic breast cancer in postmenopausal women. It is a type of hormone therapy, which works by blocking the action of the hormone estrogen in the body. It is also used to treat advanced or metastatic non-small cell lung cancer (NSCLC) in combination with certain other drugs.
Faslodex is a member of a class of drugs known as aromatase inhibitors, which are used to treat hormone receptor-positive breast cancer. It is also used in combination with other drugs to treat advanced or metastatic NSCLC. The drug works by blocking the action of the hormone estrogen in the body, which can slow the growth of certain types of cancer cells.
Faslodex is marketed by AstraZeneca and is available in the United States, Canada, and other countries. Other companies that market drugs for the treatment of lung cancer include Bristol-Myers Squibb, Eli Lilly, Merck, and Pfizer. Show Less Read more
